ESI-GROUP
18.1.2023 14:36:39 CET | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI), a global simulation and virtual prototyping software partner for the industry, has signed the United Nations Women's Empowerment Principles (WEP). The Group reaffirms its commitment to an inclusive corporate culture, guaranteeing equality between women and men: diversity at the service of the company's performance.
"By becoming a signatory to the Women's Empowerment Principles, ESI Group is committed to taking bold steps to advance gender equality in the workplace, marketplace and within the community. The Group will focus on non-discrimination, public reporting of progress toward gender equality, and on providing equal opportunities for education, training, and professional development. Diversity is key to accelerating a company's performance, enriching its culture, and employee well-being. At ESI, the workforce is multicultural, international, and comes from different areas of expertise. Women make up 43% of the Board of Directors and 50% of the management team, yet women are still underrepresented everywhere else. I am convinced that we can do better in this area and that rapidly improving the ratio of women to men in all teams will help our company to progress, satisfy employees and clients, and establish long-term performance," declares Cristel de Rouvray, CEO at ESI Group.
A priority objective for the Group
ESI Group is already committed to gender equality, notably through actions taken to promote the recruitment of women and their professional development within the industry. In May 2022, the Group set up its Women@ESI network, which strives towards strengthening internal collaboration between employees and creating a communication channel to share ideas that promote the representation of women. ESI Group confirms its intention to continue to move further.
Among the various actions in progress and to come, ESI Group will continue its policy of compensation promoting equality between women and men, based on objective market data that takes into account the position held and the level of seniority without gender consideration. ESI plans to reach 25% of women in the company by 2024 and 33% by 2028. The Group will strengthen the inclusiveness of its job offers and recruitment processes, by systematically presenting a selection of candidates composed of women and men. Furthermore, in order to materialize a safe and inclusive Group culture, ESI is committed to developing, in addition to its ethical charter, a charter further strengthening its commitment to preventing harassment. The Group will also provide a specific training on the subject of harassment to all staff. Finally, ESI Group wishes to implement a global parental leave policy for women and men by 2028.
Established by UN Global Compact and UN Women in 2010, the Women's Empowerment Principles, are informed by international labor and human rights standards and grounded in the recognition that businesses have a stake in, and a responsibility for, gender equality and women’s empowerment. There are a set of seven principles offering guidance to business on how to promote gender equality and women’s empowerment in the workplace, marketplace and community:
- 1: Establish high-level corporate leadership for gender equality,
- 2: Treat all women and men fairly at work – respect and support human rights and non-discrimination,
- 3: Ensure the health, safety and well-being of all women and men workers,
- 4: Promote education, training and professional development for women,
- 5: Implement enterprise development, supply chain and marketing practices that empower women,
- 6: Promote equality through community initiatives and advocacy,
- 7: Measure and publicly report on progress to achieve gender equality.
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1100 people around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005552/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom